Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)

Abstract Background Nab‐paclitaxel (nab‐PTX) has better transfer to tumor tissue than cremophor‐based paclitaxel. It suggests that the optimum dose of nab‐PTX might be lower than the dose and schedule that is widely used. We designed a randomized phase II trial to examine the clinical utility and sa...

Full description

Bibliographic Details
Main Authors: Susumu Takeuchi, Kaoru Kubota, Shunichi Sugawara, Satoshi Teramukai, Rintaro Noro, Kei Fujikawa, Takashi Hirose, Shinji Atagi, Seigo Minami, Shinichiro Iida, Hiroshi Kuraishi, Tomoiki Aiba, Yuji Minegishi, Masaru Matsumoto, Masahiro Seike, Akihiko Gemma, Masaaki Kawahara, Japan‐Multinational Trial Organization (JMTO)
Format: Article
Language:English
Published: Wiley 2023-04-01
Series:Cancer Medicine
Subjects:
low dose
nab‐paclitaxel
non‐small cell lung cancer
phase II trial
previously treated
Online Access:https://doi.org/10.1002/cam4.5652

Internet

https://doi.org/10.1002/cam4.5652

Similar Items